Lennart Kühl

7PUBLICATIONS
30CO-AUTHORS
BiomaterialsMolecular targetsMedical devicesCancer therapy (excl. chemotherapy and radiation therapy)Biologically active molecules
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Sep 11, 2026
The FAP × CD3 bispecific antibody OMTX305 induces T cell-mediated antitumor effects in patient-derived ex vivo models of solid tumors.

|May 19, 2026
Novel bispecific T-cell engagers overcoming acquired EGFR resistance.

|Mar 02, 2023
eIg-based bispecific T-cell engagers targeting EGFR: Format matters.

Lennart Kühl, Annelie K Schäfer, Sebastian Kraft

|Apr 15, 2022
The eIg technology to generate Ig-like bispecific antibodies.

Lennart Kühl, Nadine Aschmoneit, Roland E Kontermann

|Mar 05, 2022
Triple Targeting of HER Receptors Overcomes Heregulin-mediated Resistance to EGFR Blockade in Colorectal Cancer.

Alexander Rau, Nicole Janssen, Lennart Kühl

|Jan 27, 2022
Fc-based Duokines: dual-acting costimulatory molecules comprising TNFSF ligands in the single-chain format fused to a heterodimerizing Fc (scDk-Fc).

Nadine Aschmoneit, Katharina Kocher, Martin Siegemund

Pageof 2

Frequent Collaborators

6 joint publications

Roland E Kontermann

6 joint publications

Oliver Seifert

4 joint publications

Nadine Aschmoneit

4 joint publications

Monilola A Olayioye